The Manufacturers Life Insurance Company Has $905,000 Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

The Manufacturers Life Insurance Company raised its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 10.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,282 shares of the company’s stock after acquiring an additional 3,112 shares during the period. The Manufacturers Life Insurance Company owned about 0.09% of Tarsus Pharmaceuticals worth $905,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of TARS. Jennison Associates LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 1st quarter valued at approximately $48,380,000. Assenagon Asset Management S.A. acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $28,904,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Tarsus Pharmaceuticals by 1,113.5% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock worth $32,642,000 after acquiring an additional 824,000 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Tarsus Pharmaceuticals during the first quarter worth $12,640,000. Finally, Millennium Management LLC lifted its position in Tarsus Pharmaceuticals by 1,259.3% in the 2nd quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after acquiring an additional 322,942 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TARS has been the subject of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $51.60.

Tarsus Pharmaceuticals Trading Up 0.6 %

Shares of Tarsus Pharmaceuticals stock opened at $35.71 on Monday. The stock has a market cap of $1.36 billion, a P/E ratio of -7.97 and a beta of 1.07. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. Tarsus Pharmaceuticals, Inc. has a 12-month low of $12.57 and a 12-month high of $42.50. The business’s 50 day moving average is $29.62 and its 200-day moving average is $31.07.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million for the quarter, compared to analyst estimates of $31.30 million. During the same period in the prior year, the firm posted ($1.17) earnings per share. Equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.68 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.